EYEZONE Magazine

EYEZONE: News

New drops are better than a needle in the eye


A new treatment for age-related macular degeneration hopes to replace an injection into the eye with simple eye drops
 (Credit: ia__64/Depositphotos)

 

 

 

 

 

 Rich Haridy
Age-related macular degeneration (AMD), is a common eye disorder that can result in the loss of one's central vision. A team of scientists has developed a new treatment for the disorder that replaces the current monthly injection into the eye with a simple eye drop.

Just in the UK alone AMD affects over 600,000 people, and in the United States the disease is the most common cause of vision loss for people over the age of 50. Treatment at the moment consists of unpleasant injections directly into the eye. These injections not only have a risk of damaging the eye but we can all agree that the thought of having a needle inserted into our eyeball is about as off-putting as a medical procedure gets.

Thankfully a team of scientists from the University of Birmingham has developed a groundbreaking new treatment that can deliver the drug as an eye drop instead of an injection. The team produced a cell-penetrating peptide (CPP) that can carry the drug to the relevant part of the eye within minutes.

The newly published study highlights effective, and non-toxic, delivery of AMD treating drugs using the CPP method into mouse, rat and pig eyes. The bioactivity of the eye-drops was demonstrated as equivalent to any alternate drug-delivery method. "The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionizing drug-delivery options," says Dr Felicity de Cogan. "Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments."

The CPP development means that drugs which need to be delivered directly to the posterior chamber of the eye could now be administered with a simple eye-drop instead of through invasive injections. While the team's initial studies have been in the delivery of AMD treatments, they do point out that this research could potentially be applied to other chronic ocular diseases.

The research was published in the journal Investigative Ophthalmology and Visual Science.

Source: University of Birmingham (newatlas.com)

Camera glasses flip out when the shooting starts


FaceShot glasses, seen here in recording mode (Credit: Omni Wearables)

 

 

 

Ben Coxworth
The past several years have brought us a number of sunglasses with built-in video cameras, and the concept is kind of clever – you can record videos from your point of view, keeping your hands free the whole time. Unfortunately, though, many people don't like the thought of users recording them without their knowledge. Well, that's where Omni Wearables' FaceShot glasses come in. Their camera flips forward when in use, making it obvious that a recording is taking place.

From the sounds of things, using the FaceShots is pretty simple.

When the 1080p/30fps wide-angle camera is docked flush with the left temple arm of the glasses, it's turned off. When you want to record, you just flip it forward – it automatically powers up and starts recording, saving footage to an onboard microSD card. According to the company, one USB charge of the built-in battery should be good for at least 1.5 hours of recording.

Depending on what sort of footage you're hoping to capture, the camera can also be angled up or down 15 degrees. And yes, there is a mic for recording sound, and the glasses themselves do block 99 to 100 percent of UV-A and UV-B rays.

Should you be interested in getting a set of the glasses, they're currently the subject of a Kickstarter campaign. A pledge of US$199 will get you a pair, when and if they're ready to go. The planned retail price is $299.

Sources: Omni Wearables, Kickstarter (newatlas.com)

Safilens Debuts a New Generation of Contact Lenses


 

 

 

 

Founded in 2001, Safilens, an industry leader known for its high-performance optical care products, aimed at creating innovative, high-quality products for the contact lens industry. It is a robust, innovation-minded company that brilliantly puts its founders’ more than 30 years of experience into developing products that are always in sync with market developments and the needs of contact lens wearers. The company’s core value lies in the excellence of its R&D department and its focus on customer care.

The future of contact lenses

Safilens believes in real benefits and advantages and always takes inspiration from the human body, from its natural dynamics and from its incredible ability to resolve almost all problems independently. This led to the creation of contact lenses that release a natural tear substitute. Safilens research believes that releasing bio-active substances is the key to being able to physiologically restore the delicate contact lens-tear film relationship.

Innovation you can see

The characteristics of the two natural polymers (TSP and Hyaluronic Acid) suggested a possible synergy that amplifies the already well-known properties of hydrating, lubricating and protecting the ocular surface, and encouraging the regrowth of the epithelial microvilli.

Focus on Hyaluronic Acid and TSP – fusion technology

Hyaluronic Acid is one of the most absorbent molecules to be found in nature. The exceptional hydro-absorbent properties of this biopolymer improve the hydration of the interfaces, increase corneal residence time, increase volume of tears, stabilize tears, as well as, improve tolerability, re-epithelialization, and friction reduction. TSP (Tamarind Seed Polysaccharide) has a branched molecular structure which makes its solution similar to natural tears, and is what is behind its mucoadhesive properties. TSP is a natural polymer that is extracted from tamarind seeds. Its characteristics give it enormous muco-adhesive properties, without excessively increasing the viscosity of the solution, while displaying extreme tolerability. It is also neither toxic nor irritating, and it hydrates, protects, as well as, lubricates.

The lens

Fusion technology allows using the synergic interaction between Hyaluronic Acid and TSP to create an entirely natural biocopolymer, which is inserted into the plastic material of the contact lens, using a Safilens-patented, thermo-reversible hydration process.

Focus on Open Care System

The ‘Open Care System’ consists of contact lens, ‘Open Reload’ and ‘Sonic Wave Generator’. As a result of the fusion technology, the lens benefits from the combined action of Hyaluronic Acid (HA) and Tamarind Seed Polysaccharide (TSP): this synergy increases the hydrating, lubricating, mucomimetic, protective and cellular regeneration effect of the two single polymers, and promotes tear film stability. ‘Open Reload’ is an all-in-one solution containing highly-concentrated fusion co-polymer based on a superior quality Hyaluronic Acid. ‘Sonic Wave Generator’ assures that any deposit build-up is removed and HA and TSP are reabsorbed during the night, for a regenerated lens every day.

Tawazi Optical Trading LLC, a certified partner of Safilens, has a robust geographical presence across the Middle East, Africa, Turkey, and India. The company prides of its wide range on worldrenowned products designed with innovation at its core.
Newly-elected President Morel Envisions SILMO Paris’ Future on its 50th Milestone


Amélie Morel, the new SILMO Paris president, shares her thoughts over the 50th anniversary of SILMO, one of the leading optics and eyewear exhibitions across the globe. It has relentlessly pitched innovations to ensure the exhibition remains at the forefront of market developments. For the past 50 years, SILMO has been birthing tools and promotional platforms, such as SILMO d’Or awards, SILMO Academy, and Trends Forum, to name a few, to sculpt a niche as the flagship trade fair for industry professionals. It can be recalled that as former Communications Director for the Morel Company, Amélie bagged a unanimous vote for the position after Philippe Lafont passed away in March. When asked how the appointment has impacted her career, Morel believes it has brought honor to her family, and that she has committed to preserving SILMO’s worthy spot in the international optical scene.

How did you receive the news of your new nomination?

I was flattered and enthusiastic. Representing an institution like this one is a great opportunity and, of course, a huge responsibility. SILMO is an “incredible machine”, receiving professionals from throughout the world. They expect a lot from this annual fair in terms of business, but also in terms of trends, market understanding and discussions.

What are the outstanding moments in SILMO’s history?

The fair was founded in 1967 in Oyonnax, in the French birthplace of glasses manufacture. It moved to Paris 15 years later to enhance and facilitate its international position. By the end of the 1980s, “fashion was fashionable” and SILMO introduced the trend forums and presented shows of unique glasses. In 1993, the organisers decided that the date of the trade fair that animates an entire industry should be in autumn. During the same decade, SILMO anticipated the changes in the sector, founding the Village to host creative new brands, and the first SILMO d’Or international awards for creation and innovation. The fair’s 40th anniversary also illustrated the international reputation of SILMO, with a record number of visitors. We hope that the 2017 jubilee will be equally appreciated.

How do you see the SILMO fair expanding and evolving in the future?

We are celebrating the 50th anniversary of the fair with a serene and constructive approach to prepare the next 50 years. SILMO maintains its place as a market leader and remains a reference among optical fairs, but we must not rest on our laurels. We are well aware that self-criticism is essential to be able to anticipate change in the world markets and to assist professionals with their business transformations, and current and future mutations. We also strive to preserve a fair balance between French and international visitors, after all, need it be reminded, the French market is the largest in Europe. The SILMO brand must continue to shine and maintain its development in the markets of the future, helping the industry’s business to grow.
قطرات جديدة أفضل من غرز الإبرة في العين

علاج جديد لمرض الضمور البقعي المرتبط بالشيخوخة يفتح أملاً باستعمال قطرة عين بسيطة عوضاً عن غرز الإبرة في العين.

 

 





 

ريتش هاريدي

إن مرض الضمور البقعي المرتبط بالشيخوخة هو اعتلال شائع يصيب العين ويمكن أن ينتج عنه فقدان البصر بشكل رئيسي. طور فريق من الباحثين علاجاً جديداً لهذا الإعتلال بحيث يعمل كبديل عن غرز الابرة في العين شهرياً وذلك بواسطة قطرة عين بسيطة.

في المملكة المتحدة وحدها هناك 600000 مصاب بمرض الضمور البقعي ويعتبرفي الولايات المتحدة الأمريكية من أكثر أسباب فقدان البصر شيوعاً للأشخاص الذين تتجاوز أعمارهم الخمسين. يتضمن العلاج حالياً استخدام إبر تغرز مباشرة في العين. هذه الإبر لا تشكل خطراً بإحداث تلف في العين وحسب بل يمكننا جميعاً أن نتفق على أن غرز الإبرة في العين إنما هو من أكثر المعالجات إزعاجاً من بين الإجراءات الطبية المتبعة.

من حسن الحظ قام فريق من العلماء في جامعة برمنجهام بتطوير علاج مبتكر يمكنه أن يطرح الدواء كقطرة للعين بدلاً من الإبرة. أنتج الفريق مادة الببتايد المخترقة للخلايا (CPP) التي تستطيع أن تحمل الدواء للجزء المطلوب في العين خلال دقائق.

الدراسة الجديدة التي نشرت مؤخراً تسلط الضوء على فعالية العلاج الغير سمي لمرض الضمور البقعي باستخدام منهج (CPP) على عيون الفئران والخنازير والجرذان الكبيرة. وقد تمت ملاحظة أن النشاط الحيوي لقطرات العين يعادل أي أسلوب آخر لإيصال الدواء.

يقول الدكتور فيليستي دي كوجان : " إن عقار (CPP) لديه إمكانية إحداث تأثير كبير في علاج مرض الضمور البقعي بواسطة هذه الخيارات الثورية في إيصال العلاج. إن التطبيق الفعال للدواء الذي يتفاعل ذاتياً بواسطة قطرة العين سوف يقودنا إلى تخفيض كبير في النتائج السلبية وتكاليف العناية الصحية مقارنة مع وسائل العلاج الحالية."

إن تطوير عقار (CPP) يعني أن العلاج الذي يراد منه أن يصل مباشرة إلى الحجرة الخلفية للعين يمكن أن ينجز الآن بواسطة قطرة عين بسيطة بدلاً من غرز الإبر. في الوقت الذي كانت الدراسات الأولية للفريق تهدف إلى تحقيق علاجات لمرض الضمور البقعي، تم التنويه بأن هذه الدراسات قد يمكن تطبيقها على أمراض بصرية أخرى.

Investigative Ophthalmology and Visual Science. تم نشر هذا البحث في صحيفة

المصدر : جامعة برمنجهام
كاميرا مدمجة في النظارة تظهر عند البدء في التصوير

نظارة فيسشوت، تظهر هنا أثناء التصوير (المصدر أومني ويرابلز)




 

 

 

مايكل ايرفنج شاهدنا في السنوات الماضية عدداً من النظارات الشمسية مدمجة بكاميرات فيديو، والفكرة ذكية نوعا ماً،فهي تستطيع أن تسجل مقاطع من الفيديو من زاوية رؤيتك، مع إراحة يديك طول الوقت. مع ذلك ولسوء الحظ فإن العديد من الناس لا يحبون فكرة أن يصورهم أحدهم دون علمهم. حسناً، بإمكان نظارة فيسشوت من إنتاج أومني ويرابلز أن تحل المشكلة، فهذه الكاميرا تتحرك إلى الأمام أثناء الاستخدام، مما يجعلها ظاهرة بوضوح أثناء التصوير.

من حيث الآلية التي تعمل بها الأشياء فإن استخدام فيسشوت بسيط للغاية.

عندما تكون هذه الكاميرا ذات الزاوية الواسعة 1080p/30fps ملتصقة بالذراع الأيسر من النظارة فهي اذن مطفأة. عندما تريد أن تبدأ بالتسجيل حركها إلى الأمام وستشتغل اوتوماتيكياً وستبدأ التصوير ومن ثم حفظ اللقطات في بطاقة microSD الموجودة فيها. طبقاً لما أوردته الشركة فإن شحنة واحدة من USB في البطارية المدمجة سيكون صالحا للتسجيل لمدة 1.5 ساعة على الأقل.

بحسب نوعية اللقطات التي تأمل أن تلتقطها، تستطيع توجيه زاوية الكاميرا 15 درجة إلى الأعلى أو الأسفل. بالطبع يوجد أيضاً ميكروفون لتسجيل الصوت، والنظارة تستطيع أن تمنع 99 إلى 100 بالمئة من الأشعة فوق البنفسجية A و B.

إذا كنت مهتماً بشراء هذه النظارة، فإنها جاهزة حالياً لإطلاقها ضمن حملة ترويجية. يمكن أن تحصل عليها بسعر 199 دولار أمريكي متى ما قرروا اطلاقها، والسعر المقرر تثبيته فيما بعد سيكون 299 دولار أمريكي.

المصدر: أومني ويرابلز

 

 

P.O. Box 4103, Safat 13042, Kuwait. • Tel: +965 2245 4597 • Fax: +965 2245 4596 • Email: eyezonemag@yahoo.com
All rights reserved. EYEZONE Magazine. • Copyright ©